Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
|Articles|June 15, 2018
- BioPharm International-06-15-2018
- Volume 2018 eBook
- Issue 2
Assurance of Supply
Author(s)Adeline Siew, PhD
Robust materials management, supplier quality management, quality control, and business continuity planning are essential to ensure continuous supply of single-use bags.
Advertisement
Single-use bags are widely used in biopharmaceutical manufacturing. A crucial aspect for drug manufacturers is the reliability of the supply chain of single-use bags. BioPharm International spoke to Sara Bell, senior marketing manager, Single-Use Solutions, MilliporeSigma, about the supply-chain challenges from a single-use supplier’s perspective.
Read
Article Details
BioPharm International
eBook: Single-Use Systems 2018
Vol. 31
June 2018
Pages: 30, 32–33
Citation
When referring to this article, please cite it as A. Siew, "An Integrated Approach to Shipping Liquid in Single-Use Systems," BioPharm International Single-Use Systems 2018 eBook (June 2018).
Articles in this issue
over 8 years ago
Considering Silicone Tubing and Assembliesover 8 years ago
Qualification of Single-Use Systemsover 8 years ago
Managing Quality in Single-Use Systemsover 8 years ago
Comparing the Supply Lifecycle of Bioreactorsover 8 years ago
Biosimilars and Biobetters Strategies and Challengesover 8 years ago
An Integrated Approach to Shipping Liquid in Single-Use Systemsover 8 years ago
Single-Use Boosts Fill/Finish in Commercial BiomanufacturingAdvertisement
Related to this article
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Phio's PH-762 posted a 70% response rate in skin cancer, supporting its FDA briefing package for a planned phase 2b trial.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
With 15 patients now dosed in its pivotal EMERALD trial, Resolution will build on the 70% 4-year transplant-free survival seen with RTX001 in earlier data.
Advertisement
Advertisement